Zydus Lifesciences Limited reported a 30 per cent year-on-year increase in net profit to ₹1,023.5 crore for the quarter ended December 31, 2024, driven by robust performance in its US ...

Zydus Lifesciences’ (Zydus) Q3FY25 revenue was in line with our expectations, but lower sales of gRevlimid and gAsacol led to a miss in earnings. Higher sales of Mirabegron and new launches led ...

- Per. of shares (as a % of the total sh. of prom. and promoter group)----- - Per. of shares (as a % of the total Share Cap. of the company)----- Advisory Alert: It has come to our attention ...

(Image Credits: Pixabay) Zydus Lifesciences Ltd on Wednesday reported a profit of Rs 1023.80 crore during the third quarter of FY25, posting a growth of 29.66 per cent in comparison to Rs 789.60 ...

India], January 31: Zydus Takeda Healthcare Private Limited (ZTHPL), a joint venture company set up by Zydus Lifesciences Limited and Takeda Pharmaceutical Company Limited (Takeda) (TSE:4502/NYSE:TAK) ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Zydus Wellness Ltd. is a Public Limited Listed company incorporated on 01/11/1994 and has its registered office in the State of Gujarat, India. Company's Corporate Identification Number(CIN) is ...

Zydus Lifesciences Q3 Earnings: Zydus Lifesciences reported a 30% YoY rise in Q3FY25 net profit to ₹1,023.5 crore, driven by strong US growth. Revenue increased 17% YoY, while EBITDA rose 26%. The ...

Zydus Lifesciences Q3 profit rises 30% to Rs 1,023 crore, driven by strong US and domestic market sales. Revenue also increased significantly, indicating robust growth. New Delhi, Feb 5 (PTI) Zydus ...

Zydus Lifesciences Ltd. reported US formulation sales that were ahead of expectations during the December quarter on Wednesday, February 5. Despite this, the stock has declined to the lows of the day.

On Wednesday, 72 companies are set to report their financial performance for the quarter ended December. Zydus Lifesciences Ltd. is expected to clock a revenue of Rs 5,204 crore. Its earnings before ...